Louis Nisbet has become chairman of BioCity Nottingham in the UK. He will oversee the expansion of BioCity’s services to cater for increasing demand from both UK and international tenants. The recent arrival of former AstraZeneca and Pfizer employees launching new ventures, as well as the rapid growth of several existing tenants, makes the BioCity bioscience cluster an attractive central UK business location.
Marlow-based Nisbet is a venture partner with Kurma BioFund, Paris. His early pharmaceutical career in drug discovery research with Roche, Glaxo and Smith Kline gives him a global insight into the issues surrounding the development and commercialisation of new healthcare products and businesses. He will devote time in Nottingham with fellow Board directors to addressing the needs of new life science companies, in particular their financing requirements.
Nisbet said: ‘We will be looking to work with our clients and the large pharmaceutical companies, as well as private investors, to find innovative solutions to facilitate partnerships and financing that will suit everyone.’
Dr Louis Nisbet leads BioCity forward
BioCity Nottingham appoints new chairman
You may also like
Manufacturing
Nulogy launches Supplier Compliance Management to build stronger, more resilient supplier networks
Nulogy, a leading provider of manufacturing operations software, announced the launch of Nulogy Supplier Compliance Management, a solution designed to centralise and automate supplier compliance for procurement, supply chain, and quality assurance teams in manufacturing, food & beverage, pharmaceuticals, and
other highly regulated industries
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Finance
Investing in the future of healthcare: from diagnostics innovation to scientific talent pipelines
Strategic UK investment in next-generation cancer diagnostics and cardiovascular research training is accelerating innovation, reducing barriers to adoption and building the multidisciplinary talent needed to deliver long-term improvements in patient outcomes and life sciences growth
Research & Development
Just – Evotec Biologics wins BARDA contract to optimise antibody biomanufacturing against Ebola and Sudan virus
Just – Evotec Biologics has been selected by BARDA to develop scalable, high-yield manufacturing processes for a monoclonal antibody cocktail targeting filovirus diseases under a multi-year programme valued at up to $10m